A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer progressed on gemcitabine-based therapy

被引：0
|
作者：
Grierson, Patrick
Wang-Gillam, Andrea
Park, Haeseong
Pedersen, Katrina
Tan, Benjamin R.
Amin, Manik A.
Suresh, Rama
Trikalinos, Nikolaos
Liu, Jingxia
机构：
[1] Washington Univ, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Mayo Sch Grad Med Educ, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS793
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
    Loupakis, Fotios
    Masi, Gianluca
    Fornaro, Lorenzo
    Vasile, Enrico
    Allegrini, Giacomo
    Fontana, Eloise
    Granetto, Cristina
    Salvatore, Lisa
    Mentuccia, Lucia
    Andreuccetti, Michele
    Cortesi, Enrico
    Merlano, Marco
    Cascinu, Stefano
    Falcone, Alfredo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (03) : 559 - 566
  • [22] Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew
    Shan, Yang-Shen
    Jameson, Gayle S.
    Macarulla, Teresa
    Lee, Kyung-Hun
    Cunningham, David
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Braiteh, Fadi S.
    Moyo, Victor M.
    Belanger, Bruce
    Bayever, Eliel
    Von Hoff, Daniel D.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [23] A case of pathological complete response with liposomal irinotecan+5-FU/LV for unresectable locally advanced pancreatic cancer
    Kikuchi, Koji
    Umemura, Akira
    Nitta, Hiroyuki
    Katagiri, Hirokatsu
    Nishiya, Masao
    Uesugi, Noriyuki
    Sugai, Tamotsu
    Imanari, Keisuke
    Sasaki, Akira
    SURGICAL CASE REPORTS, 2022, 8 (01)
  • [24] Gemcitabine and protracted 5-FU for advanced pancreatic cancer.: A phase II study
    Kurtz, JE
    Kohser, F
    Négrier, S
    Trillet-Lenoir, V
    Walter, S
    Limacher, JM
    Untereiner, M
    Kayitalire, L
    Jaeck, D
    Dufour, P
    HEPATO-GASTROENTEROLOGY, 2000, 47 (35) : 1450 - 1453
  • [25] Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy
    Pelzer, U.
    Blanc, J. -F
    Melisi, D.
    Cubillo, A.
    Von Hoff, D. D.
    Wang-Gillam, A.
    Chen, L. -T
    Siveke, J. T.
    Wan, Y.
    Solem, C. T.
    Botteman, M.
    Yang, Y.
    de Jong, F.
    Hubner, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 260 - 260
  • [26] Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Chen, L-T.
    Wang-Gillam, A.
    Li, C-P.
    Bodoky, G.
    Dean, A.
    Shan, Y-S.
    Jameson, G. S.
    Macarulla, T.
    Lee, K-H.
    Cunningham, D.
    Blanc, J-F.
    Hubner, R.
    Chiu, C-F.
    Schwartsmann, G.
    Braiteh, F.
    Belanger, B.
    Bayever, E.
    de Jong, F.
    von Hoff, D. D.
    Siveke, J. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] Efficacy of liposomal-irinotecan (nal-IRI) plus 5-fluorouracil/folinic acid (5-FU/LV) versus oxaliplatin plus fluoropyrimidines in previous gemcitabine treated pancreatic adenocarcinoma (PAC) patients (pts).
    Kieler, Markus
    Unseld, Matthias
    Bianconi, Daniela
    Scheithauer, Werner
    Prager, Gerald W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [28] Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)
    Modest, Dominik Paul
    Heinemann, Volker
    Schuett, Philipp
    Angermeier, Stefan
    Haberkorn, Mike
    Waidmann, Oliver
    Graeven, Ullrich
    Wille, Kai
    Kunzmann, Volker
    Henze, Larissa
    Constantin, Christian
    de Wit, Maike
    Denzlinger, Claudio
    Ballhausen, Alexej
    Kurreck, Annika
    Jelas, Ivan
    Alig, Annabel Helga Sophie
    Stahler, Arndt
    Stintzing, Sebastian
    Oettle, Helmut
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (07)
  • [29] Impact of bevacizumab plus 5-FU/LV with or without irinotecan on quality of life in patients with metastatic colorectal cancer
    Chawla, A.
    Holmgren, E.
    Nelson, B.
    Cella, D.
    Yost, K.
    Hurwitz, H.
    Kabbinavar, F.
    Novotny, W.
    Mrad, R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 367 - 367
  • [30] Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Chen, L. -T.
    Siveke, J.
    Wang-Gillam, A.
    Hubner, R.
    Pant, S.
    Dragovich, T.
    Chung, V.
    Chang, D.
    Ross, P.
    Cooray, P.
    Tebbutt, N.
    Franke, F.
    Belanger, B.
    Dhindsa, N.
    de Jong, F.
    Mamlouk, K.
    Von Hoff, D.
    ANNALS OF ONCOLOGY, 2016, 27 : 110 - 110
12345